Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAmpeak Energy Regulatory News (AMP)

Share Price Information for Ampeak Energy (AMP)

Share Price is delayed by 15 minutes
Get Live Data
2.70    0.00 (0.00%)
Bid:
2.60
Ask:
2.80
Spread: 0.20 (7.692%)
Market Cap: £19.52m
AMP Live PriceLast checked at - London Stock Exchange

Intraday Ampeak Energy Share Chart

IP Licensing

24 Sep 2010 07:00

RNS Number : 2356T
Amphion Innovations PLC
24 September 2010
Β 

Amphion Innovations plc

IP Licensing

Β 

London and New York, 24 September 2010 - Amphion Innovations plc (LSE: AMP) ("Amphion" or the "Company"), the developer of medical and technology businesses, today announces that its wholly owned subsidiary, DataTern, Inc., has settled certain pending patent infringement litigation over its U.S. Patents 6,101,502 and 5,937,402, generating total revenues of $500,000.

Β 

DataTern has signed 22 licenses of these patents since June 2008, generating total revenues of approximately $14 million. DataTern has now licensed its intellectual property into the financial, credit card, retail, leisure, healthcare, airline, e-commerce, and software industries.

Β 

DataTern, Inc., was originally established in order to commercialise selected intellectual property opportunities in partnership with Amphion's Partner Companies. As part of the licensing programme described above, DataTern offers to license all parties in all industries under these patents.

Β 

For further information please contact:

Amphion Innovations plc Charlie Morgan +44 779 953 6043

Β 

Cardew Group Tim Robertson/ Jamie Milton +44Β 20Β 7930Β 0777

Β 

Charles Stanley (Nominated Adviser) Mark Taylor +44Β 20Β 7149Β 6000

Β 

About Amphion Innovations plc


Amphion (LSE: AMP) builds shareholder value in high growth companies in the medical and technology sectors, by using a focused, hands-on company building approach, based on decades of experience in both the US and UK. Amphion has significant shareholding in 8 Partner Companies developing proven technologies targeting substantial commercial marketplaces, each in excess of $1 billion. Each Partner Company is chosen with the goal of achieving an exit valuation in excess of $100 million. The Amphion model has been refined to optimise the commercialisation of patents and other intellectual property within the Partner Companies. The Partner Companies collectively own or control over 200 separately identified pieces of intellectual property, a number that grows rapidly each year.

Β 

On the web: www.amphionplc.comΒ 

Β 

This information is provided by RNS
The company news service from the London Stock Exchange
Β 
END
Β 
Β 
MSCUOABRRKAKUAR
Date   Source Headline
13th Nov 20067:01 amRNSAcquisition
7th Nov 200610:24 amRNSRe: Partner Company
2nd Nov 20064:36 pmRNSDirector/PDMR Shareholding
24th Oct 20069:03 amRNSDirector/PDMR Shareholding
14th Sep 20067:00 amRNSWellGen CEO
12th Sep 20067:00 amRNSChange of Adviser
7th Sep 20067:01 amRNSInterim Results
22nd Aug 20064:00 pmRNSFireStar Software, Inc
17th Aug 20067:01 amRNSAdditional Shares Placed
9th Aug 20061:43 pmRNSIssue of Equity
24th Jul 20067:02 amRNSSeries C Financing
12th Jun 20064:58 pmRNSResult of AGM
8th Jun 20067:03 amRNSAGM Statement
8th Jun 20067:01 amRNSAppointment
6th Jun 20067:01 amRNSRe Agreement
5th Jun 20063:16 pmRNSThe Shafallah Center
2nd Jun 20065:01 pmRNSDr David Evans
1st Jun 20067:00 amRNSAnnual Report and Accounts
23rd May 20067:00 amRNSDirector/PDMR Shareholding
22nd May 20061:41 pmRNSDirector/PDMR Shareholding
19th May 20065:12 pmRNSDirector Share Transaction
15th Mar 20069:25 amRNSCompletion of a Financing
8th Mar 20067:04 amRNSFinal Results
2nd Mar 20069:12 amRNSMotif BioSciences
27th Feb 20064:56 pmRNSNotice of Results
23rd Feb 20067:02 amRNSRe: WellGen Financing
3rd Jan 20067:01 amRNSAdditional Investments
5th Dec 200512:48 pmRNSDirector Shareholding
10th Oct 20057:00 amRNSAcquires a stake
21st Sep 20057:00 amRNSStake in Spin-Out Company
30th Aug 20057:00 amRNSAmphion Invests in WellGen
25th Aug 20054:50 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.